Skip to main content

Table 1 Patient characteristics

From: High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease

Patients (n, %)

714

100

   Male (n, %)

345

48.3

   Female (n, %)

369

51.7

Age, years (median, IQR)

35

30 - 42

   Clinical stage

  

   CDC A (n, %)

354

49.6

   CDC B (n, %)

158

22.1

   CDC C (n, %)

202

28.3

CD4+ T cell count, cells/μL (median, IQR)

350

220 - 533

CD4+ T cells, percent (median, IQR)

21.0

15.0 - 29.0

CD8+ T cell count, cells/μL (median, IQR)

808

565 - 1133

CD8+ T cells, percent (median, IQR)

51.0

41.0 - 59.0

Patients with HIV-1 RNA <50 copies/mL (n, %)

308

43.1

Patients with HIV-1 RNA ≥50 copies/mL (n, %)

406

56.9

HIV-1 RNA among these (log [copies/mL], IQR)

3.94

2.97-4.68

HIV-1 clade (n, %)

  

   B

94

13.2

   Non-B (15 different clades)

620

86.8

Treatment status

  

   HAART-naive (n, %)

190

26.6

   Receiving HAART (n, %)

524

73.4

   Months on HAART if receiving HAART (median, IQR)

13.5

11.1 - 17.8